Teva Pharmaceutical Industries Ltd (TEVA)

34.10
NYSE : Health Care
Prev Close 34.10
Day Low/High 0.00 / 0.00
52 Wk Low/High 33.56 / 64.31
Avg Volume 10.50M
Exchange NYSE
Shares Outstanding 1.01B
Market Cap 34.26B
EPS 1.80
P/E Ratio 6.70
Div & Yield 1.36 (4.00%)

Latest News

Teva May Have Found a Cure for Last Year

Teva May Have Found a Cure for Last Year

This pharma company is still making lots of money and its stock is too cheap to pass up.

Boost in Small-Business Confidence Is a Big Deal: Cramer's 'Mad Money' Recap

Boost in Small-Business Confidence Is a Big Deal: Cramer's 'Mad Money' Recap

The small business survey signals more building, more hiring, and more buying, Jim Cramer says.

Schlumberger, Broadcom, Nucor: 'Mad Money' Lightning Round

Schlumberger, Broadcom, Nucor: 'Mad Money' Lightning Round

Jim Cramer's bullish on SLB, AVGO, NUE and FRT. He's bearish on ESV, TEVA.

Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

CEO Brent Saunders plans to reward shareholders after striking a slew of R&D acquisitions in the latter half of 2016.

Teva Announces Completion Of Sale Of UK And Ireland Actavis Assets And Operations Following European Commission Approval

Teva Announces Completion Of Sale Of UK And Ireland Actavis Assets And Operations Following European Commission Approval

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a...

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

How to Trade the Week's Most Active Stocks -- Apple, AT&T, Chesapeake Energy and More

How to Trade the Week's Most Active Stocks -- Apple, AT&T, Chesapeake Energy and More

Here's a technical look on how to trade some of the most active stocks on the market this week.

Teva To Present At The 35th Annual J.P. Morgan Healthcare Conference

Teva To Present At The 35th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 35 th Annual J.

Why Teva Pharmaceuticals Shares Are Losing Steam

Why Teva Pharmaceuticals Shares Are Losing Steam

Teva Pharmaceuticals plunged on Friday amid weaker-than-expected 2017 guidance.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Teva Provides 2017 Financial Outlook

Teva Provides 2017 Financial Outlook

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2017.

Teva To Host 2017 Business Outlook Conference Call And Webcast On January 6, 2017

Teva To Host 2017 Business Outlook Conference Call And Webcast On January 6, 2017

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will host a conference call and live webcast on Friday, January 6, 2017 at 8:00 a.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Teva's Range of Products, Reach Make It a Solid Value Play in the Drug Sector

Teva's Range of Products, Reach Make It a Solid Value Play in the Drug Sector

The stock of the world's largest maker of generic drugs is cheap right now; grab shares while there's still time.

Now's the Time to Embrace This Unloved Drug Stock

Now's the Time to Embrace This Unloved Drug Stock

Tax-loss selling and negative Wall Street sentiment will prove a boon for contrarian investors who act quickly on this beaten-down, generic drug maker.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Don't Be So Quick to Be Bullish

The ETF put/call ratio chart indicates some limited upside.

January 5 Deadline Alert: Law Offices Of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors Of Upcoming Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

January 5 Deadline Alert: Law Offices Of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors Of Upcoming Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith reminds investors of the upcoming  January 5, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Teva Pharmaceutical...

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Glancy Prongay & Murray LLP ("GPM") announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of a class (the "Class") consisting of...

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Teva Will Pay $519 Million to Settle Foreign Bribery Charges; Shares Jump

Teva Will Pay $519 Million to Settle Foreign Bribery Charges; Shares Jump

Teva's share price saw a boost on the news, jumping 2.3% from the market open. Shares hit $37.21 apiece midday Thursday.

Teva Reaches Settlement With Government On FCPA

Teva Reaches Settlement With Government On FCPA

Teva Pharmaceuticals Industries Ltd., (NYSE and TASE:TEVA) announced today the conclusion of negotiations with the United States government over violations of the Foreign Corrupt Practices Act (FCPA).

Impax Searches for a New CEO

Impax Searches for a New CEO

Impax Laboratories CEO G. Frederick Wilkinson steps down amid a Department of Justice generic price-fixing investigation. J. Kevin Buchi, who joined the board last month, was tapped as interim CEO.

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.